Floatz logo

Tislelizumab

Peritoneal Metastases

Daping Hospital and the Research Institute of Surgery of the Third Military Medical Universitymonoclonal_antibodyPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
89/ 100

Competitive context

32 Active assets in the Peritoneal Metastases cohort.

Asset / SponsorPhaseRating
Eloxatin
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3BB
FLUOROURACILUM
Ciusss de L'Est de l'Île de Montréal
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB

View all 42 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →